Showing 6671-6680 of 18626 results for "".
Primary Results of the VESALIUS-CV Trial: Evolocumab in Patients at High Cardiovascular Risk Without Prior MI or Stroke
https://reachmd.com/clinical-practice/cardiology/primary-results-of-the-vesalius-cv-trial-evolocumab-in-patients-at-high-cardiovascular-risk-without-prior-mi-or-stroke/45568/Dr. Erin Bohula reviews VESALIUS-CV trial findings on evolocumab for primary Cardiovascular prevention in patients at high CV risk without prior MI or stroke.Strategies to Address Healthcare Disparities in Patients With Endometriosis
https://reachmd.com/programs/cme/strategies-to-address-healthcare-disparities-in-patients-with-endometriosis/26291/A paradigm change that will impact your clinical practice is occurring in the diagnosis and medical management of endometriosis. Learn more!Ramping Up to Manage COVID-19 Patients
https://reachmd.com/programs/covid-19-frontlines/ramping-up-to-manage-covid-19-patients/11527/Every COVID-19 care team has unique issues based on their situation, which is why collaboration and communication is key.We CAN Fix Healthcare: The Future is NOW
https://reachmd.com/programs/book-club/we-can-fix-healthcare-future-now/8491/Dr. Stephen Klasko, President and CEO of Jefferson University, discusses ways to improve the American healthcare system.Treatment of Overt Hepatic Encephalopathy
https://reachmd.com/cme/gastroenterology-and-hepatology/treatment-of-overt-hepatic-encephalopathy/39664/Learn how PCPs can identify early signs of hepatic encephalopathy to support timely diagnosis and clinical management.Reviewing the Latest Bladder Cancer Practice Guidelines
https://reachmd.com/programs/cme/reviewing-the-latest-bladder-cancer-practice-guidelines/32675/This activity reviews the latest treatment guidelines for metastatic bladder cancer and emerging immunotherapies for muscle-invasive bladder cancer.Missing the Window in Ambulatory Patients With HFrEF on GDMT: Strategies for CV Risk Reduction
https://reachmd.com/programs/cme/missing-the-window-in-ambulatory-patients-with-hfref-on-gdmt-strategies-for-cv-risk-reduction/48813/What is the optimal timing for adding evidence-based therapies beyond GDMT in patients with HFrEF? Explore this topic with Drs. Greene and Savarese.Sustaining Visual Benefits of Photobiomodulation in Dry Age-Related Macular Degeneration
https://reachmd.com/programs/cme/Sustaining-Visual-Benefits-of-Photobiomodulation-in-Dry-Age-Related-Macular-Degeneration/35948/Learn about multiwavelength PBM for the treatment of dry AMD, including the MOA, administration, effGDMT Is Working Fine, so Why Add More Therapies for Patients With HFrEF?
https://reachmd.com/programs/cme/gdmt-is-working-fine-so-why-add-more-therapies-for-patients-with-hfref/48811/Which patients with HFrEF may benefit from additional evidence-based therapies beyond GDMT? Join Drs. Lam and Bauersachs in this case-based discussion.Rare Kidney Disease: A Parent and Caregiver’s Perspective
https://reachmd.com/programs/clinicians-roundtable/rare-kidney-disease-a-parent-and-caregivers-perspective/27027/Discover the challenges involved in managing rare kidney diseases from a caregiver’s perspective.